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ABSTRACT
Meningiomas WHO grade I and II are common intracranial tumors in adults that normally display a benign
outcome, but are characterized by a great clinical heterogeneity and frequent recurrence of the disease.
Although the presence of an immune cell inﬁltrate has been documented in these tumors, a clear
phenotypical and functional characterization of the immune web is missing. Here, we performed an
extensive immunophenotyping of peripheral blood and fresh tumor tissue at surgery by multiparametric
ﬂow cytometry in 34 meningioma patients, along with immunosuppressive activity of sorted cells of
myeloid origin. Four subsets of myeloid cells, phenotypically corresponding to myeloid-derived
suppressor cells (MDSCs) are detectable in the blood and in the tumor tissue of patients and three of them
are signiﬁcantly expanded in the blood of patients, but show no evidence of suppressive activity. At the
tumor site, a large leukocyte inﬁltrate is present, predominantly constituted by CD33C myeloid cells,
largely composed of macrophages endowed with suppressive activity and signiﬁcantly expanded in grade
II meningioma patients as compared to grade I.
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Introduction
The tumor microenvironment holds a complex network of
communications between tumor, immune and stromal cells,
20 driven by signals provided by extracellular matrix components
and by soluble factors. Such interactions inﬂuence the out-
come of the tumor, being potentially able to drive tumor
expansion or tumor regression. The complexity of the anti-
tumor immunity is emphasized by the notion that many inﬁl-
25 trating immune cells possess a dual function in the tumor
context, because of their plasticity. Therefore, the presence of
an immune inﬁltrate does not necessarily imply an anti-tumor
response or, conversely, tumor tolerance, and thus only a care-
ful characterization and analysis of the immune inﬁltrate can
30 provide information associated to disease outcome.
An evolving aspect of brain tumors’ research is the apprecia-
tion of the presence of an immune suppressive microenviron-
ment and, in fact, a number of investigators documented the
presence of several immune-mediated suppressive mechanisms.
35 Among them, myeloid-derived suppressor cells (MDSCs) have
been recognized both in the blood and at the tumor site in
patients with glioblastoma, a very aggressive tumor associated
with a poor prognosis.1,2 An intriguing aspect of MDSC biology
is their appearance in different phenotypic subsets, both of
40 monocytic and polimorphonuclear (PMN) type, probably
because of the reaction to a conditional environment induced
by the tumor. This characteristic aspect of MDSC biology, how-
ever, challenges at present their phenotypic identiﬁcation, and a
large variance has been recognized among different laboratories
45in their characterization.3 Moreover, another element of com-
plexity is the fact that phenotypic evaluation is only one ele-
ment for the analysis of MDSC, since these cells must be
accompanied by suppressive activity. In this respect, it has
recently been proposed that cells with MDSC phenotype, but
50lacking suppressive activity should be termed as MDSC-like
cells (MDSC-LC), and the role of such myeloid cell population
in early stages of cancer or initial stages of chronic inﬂamma-
tion needs to be deﬁned. Ample evidence documents the pres-
ence of MDSC in several malignant tumors of different
55histology, but data are scarce regarding benign tumors, and
absent in meningiomas.
Meningiomas are among the most common adult primary
brain tumors and although more than 90% of meningiomas are
of benign histology (grade I), the WHO classiﬁcation system
60also recognizes atypical (grade II) and anaplastic or malignant
(grade III) meningiomas. These more aggressive histologies
have a propensity for recurrence and inﬁltration of surround-
ing brain parenchyma. Surgical resection is the standard treat-
ment for symptomatic and growing tumors. Radiation therapy
65should be considered in selected situations, while chemothera-
peutic agents have been reported to be ineffective.
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Some data report the presence of tumor inﬁltrating immune
cells in meningiomas, both of myeloid and lymphoid origin, in
some cases by immunohistochemistry, in others by ﬂow cytom-
70 etry from fresh or frozen samples,4 but a clear picture of the
immune inﬁltrate, including the tolerogenic mechanisms, is
absent.
In this study, we performed an in-depth immunophenotyp-
ing of peripheral blood and fresh tumor tissue from 34 grade I
75 and II meningioma patients at surgery, along with immunosup-
pressive activity of sorted cells of myeloid origin. We document
the presence of myeloid cell subsets with the phenotype of
MDSCs in the blood, but lacking suppressive activity, and of a
large suppressive myeloid inﬁltrate in the tumor tissue.
80 Results
Identiﬁcation of different myeloid cell subsets in peripheral
blood and tumor tissue of meningioma patients. The role of
MDSCs in malignant tumors has been clearly established in
several studies, but in benign tumors it needs to be addressed.
85 To evaluate whether expansion of MDSCs is present in menin-
gioma patients,we analyzed the presence of four subsets of
MDSCs among 34 WHO grade I/II meningioma patients. To
this aim, we performed MDSC immunophenotyping in the
blood of treatment na€ıve patients undergoing surgery for tumor
90 resection and compared these values with a cohort of 34
healthy donors (HD) matched for age (Table 1). This analysis
was carried out with a 7-color panel on whole blood allowing
the simultaneous identiﬁcation of four subsets: MDSC 1:
CD14C/IL4RaC, MDSC 2: CD15C/IL4RaC, MDSC 3: Lin¡/
95 HLA-DR¡/CD11bC/CD33C, MDSC 4: CD14C/HLA-DRlow/¡.
MDSC 1 and 4 are gated on peripheral blood mononuclear cells
(PBMC) and are monocytic MDSCs (M-MDSC), MDSC 3 is an
immature cell subset, named early MDSC (eMDSC) evaluated
on peripheral blood leukocytes (PBLs), while granulocytic
100 MDSCs (MDSC 2 or PMN-MDSC) are gated on PMNs.5
As shown in Fig. 1A, meningioma patients had a signiﬁcant
expansion of circulating MDSC 1, MDSC 2 and MDSC 4 sub-
sets, while MDSC 3 were signiﬁcantly decreased as compared
to matched HD.
105 The immunosuppressive function of speciﬁc MDSC subsets
relies on multiple mechanisms, including the expression of
arginase-1 (ARG-1). It has been extensively reported, in several
tumor types,6 that depletion of arginine by arginase-expressing
myeloid cells contributes to an immunosuppressive environ-
110ment which inhibits proliferation and T cell effector functions.
We thus assayed ARG-1 levels and activity in plasma samples
from both meningioma patients and healthy donors. As shown
in Fig. 1B (left panel), we observed a signiﬁcant increase of
ARG-1 levels in plasma from meningioma patients as com-
115pared to the control group, but this was not associated to an
increase of ARG activity (right panel), that remained instead
unchanged between the two groups (Fig. 1B, right panel).
We assessed the presence of the myeloid subsets evaluated
in the blood also in tumor biopsies from the same patients.
120Thus, after tissue dissociation cells were stained with 2 panels
containing nine different markers, and MDSC subsets were
Table 1. Participants’ characteristics
Meningiomas grade I and II
n D 34pts/31 biopsies
Controls n
D 34
Sex
Male (n) 9 24
Female (n) 25 10
Median Age 59 59
Range 39-76 36-84
Steroids
Received 100% NA
Not received 0% NA
WHO classiﬁcation of patients
WHO grade I 24 NA
WHO grade II 10 NA
WHO classiﬁcation of biopsies
WHO grade I 21 NA
WHO grade II 10 NA
Figure 1. Analysis of immunosuppressive factors in meningioma patients A) Analy-
sis of four MDSC subsets on the peripheral blood of healthy donors (n D 34) and
meningioma patients (n D 32 for MDSC 1, 3, 4; n D 30 for MDSC 2).MDSC 1
(CD14C/IL4RaC) and MDSC 4 (CD14C/HLA-DRlow/¡) are gated on PBMCs, MDSC 2
(CD15C/IL4RaC) are gated among PMN and MDSC 3 (Lin¡/HLA-DR¡/CD11bC/
CD33C) were evaluated in CD15- cells, gating ﬁrst in Lin¡HLA-DR¡ and then in
CD33C/CD11bC cells. B) Evaluation of ARG-1 levels and functional activity in the
plasma of meningioma patients (HD D 22; MG D 32). Mean §SE is reported.
Mann-Whitney U test was performed. Asterisks denote signiﬁcant P values: P<.
001. C) Levels of MDSC subsets in tumor biopsy of meningioma patients (n D 24
for MDSC 1and 2,; n D 28 for MDSC 3; n D 26 for MDSC 4) are reported in the
graphs, referred to leukocytes. Mann-Whitney U test was performed. Asterisks
denote signiﬁcant P values: P < 0.01; P <. 001.
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analyzed using the gating strategy shown in Supplementary
Fig. 1. MDSC 1 and MDSC 4 were identiﬁed among CD15¡
cells, while MDSC 2 were gated in the CD15C subset and
125 MDSC 3 were discriminated from the whole leukocyte popula-
tion as Lin¡/HLA-DR¡ cells expressing CD33 and CD11b.
This analysis revealed that MDSC levels are detectable in the
tumor inﬁltrate, and the most expanded subsets are the mono-
cytic subsets 1 and 4, while MDSC 2 and 3 are less abundant
130 (Fig. 1C). MDSC levels both in the peripheral blood and at
tumor site were also analyzed stratifying meningioma patients
on the basis of the WHO grade (I or II) but we did not observe
statistically signiﬁcant variations (data not shown).
Composition of myeloid and lymphoid cell inﬁltrate in
135 meningiomas. To characterize the immune contexture in
meningiomas at the time of surgery, we performed multicolor
ﬂow cytometry analysis with 3 panels covering 14 antigens
(Suppl. Fig. 1 and Suppl. Fig. 2) thus allowing the measurement
of expression of immune cells inﬁltrating the tumor in each
140patient. This analysis demonstrated the presence of a large and
well-deﬁned pattern of expression of tumor inﬁltrating myeloid
cells. Suppl. Fig. 2 shows the gating strategy used to identify the
different cell subsets present in the tumor microenvironment,
which are then summarized in Fig. 2A and 2B. We observed
145that more than 50% of the live cells were CD45C leukocytes
(59.5§25.6%) and, interestingly, that the large majority is con-
stituted by myeloid cells (79.8§ 14.6%), as determined by the
CD33 expression (Fig. 2A and 2B). Myeloid cells at the tumor
site are often a complex mixture of cells including granulocytes,
150tissue-resident and bone-marrow derived macrophages, and
MDSCs. Therefore, to dissect the presence of different myeloid
cells, we added HLA-DR marker that allowed us to distinguish
three different myeloid subsets, CD33C/HLA-DRC, CD33C/
Figure 2. Characterization of myeloid and lymphoid populations present at the tumor site. A) Representation of the levels of different cell subsets contained in tumor
biopsies of meningioma patients. B) The mean and SD are reported in the table. C) CD33C/HLA-DRC (left panel) and CD33dim/HLA-DR¡ cells (right panel) were evaluated
in grade I (n D 23) and grade II (n D 11) meningioma patients. D) Frequency of PD-L1 in CD45¡ cells, and in CD33C, CD33C/HLA-DRC, CD33dim/HLA-DR¡ cells are
reported in the graph (n D 28). E) PD-1C(left panel) and LAG-3C cells(right panel) were calculated in CD3C/CD8¡ and CD3C/CD8CT cell subsets (nD 24). F) LAG-3 expres-
sion was analyzed in CD3C/CD8¡ cells in grade I (n D 16) and grade II (n D 8) meningioma patients. Mann-Whitney U test was performed. Asterisks denote signiﬁcant P
values: P <. 05; P <.01.
B=w in print; colour online
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HLA-DRdim and CD33dim/HLA-DR¡ cells. We thus separated
155 by FACS sorting CD45¡ cells, lymphocytes, CD33C/HLA-DRC
and CD33dim/HLA-DR¡ myeloid cells and prepared a cytospin
for morphological evaluation. CD33C/HLA-DRC cells corre-
spond phenotypically and morphologically to macrophages,
while CD33dim/HLA-DR¡ correspond to PMNs (Suppl. Fig. 2).
160 CD33C/HLA-DRdim cells match phenotypically to MDSC 4
since they are also CD14C (data not shown). Macrophages rep-
resent the 80.4§ 20.6% of total CD33C cells, PMN the 16.2 §
17.6% and MDSC 4 the 3.4 § 4.2% (Fig. 2B). Of note, we found
that in grade II meningiomas there is a signiﬁcantly higher
165 presence of macrophages, as compared to grade I tumors and a
signiﬁcantly lower level of PMNs (Fig. 2C).
In the same tumor tissue, we also determined the presence
of T cells, along with the cell-surface molecules related to T cell
responsiveness. To analyze T cells, we ﬁrst gated on CD33¡
170 population, that phenotypically and morphologically corre-
sponds to lymphocytes (Suppl. Fig. 2), and then used CD3 and
CD8 markers to identify CD3CCD8¡ and CD3CCD8C T cells.
CD33¡ cells constitute the 19.2§14.0% of leukocytes present at
the tumor site and they contain 29.9§14.3% of CD3CCD8¡ T
175 cells and 49.0§14.7% of CD8C T cells, representing, respec-
tively, 6.5 § 8.0 and 8.7 § 5.1% of total leukocytes (Fig. 2B).
We next analyzed in the immune inﬁltrate the expression of
PD-L1, a molecule involved in immunoregulatory pathways
and in the mechanism of suppression of MDSCs.7 Our results
180 show that PD-L1 is present at high levels in CD45¡
cells (mean: 74.3§22.3%), but its expression was present also
on myeloid cells (CD33C mean 20.7§15.1%, CD33C/HLA-
DRC mean 24.7§21.5% and CD33dim/HLA-DR¡ mean
21.2.1§14.5%), although at lower levels. On average, the
185 expression does not differ between macrophages and PMNs,
but the macrophages of some patients show a very high expres-
sion of PD-L1, comparable to that of tumor cells (Fig. 2D).
Since PD-L1 was expressed on tumor and myeloid cells, we
checked whether its receptor PD-1 was increased on inﬁltrating
190 T cells, and observed a very high expression of PD-1 on CD3C
T cells (mean 83.8§9.8%, data not shown), with signiﬁcantly
higher levels in CD3CCD8C T cells as compared to CD3CCD8¡
T lymphocytes (Fig. 2E, left panel). Besides PD-1, we also eval-
uated LAG-3 expression on T cells, a marker that is involved in
195 T cell exhaustion8,9 and up-regulated in T cells after the co-cul-
ture with in vitro-induced MDSCs.7 Our data indicate that
LAG-3 is expressed in CD3C T cells inﬁltrating meningioma
biopsies (mean 19.2§8.3%, data not shown) and that it reaches
comparable levels in CD3CCD8¡ and CD3CCD8C T cells
200 (mean 19.3§8.2% in CD3CCD8¡ T cells; mean 19.5§9.3% in
CD3CCD8C T cells) (Fig. 2E, right panel). Interestingly, we
found that LAG-3 expression was signiﬁcantly higher in
CD3CCD8¡T cells of grade II meningiomas, compared to grade
I (Fig. 2F).
205 Functional characterization of myeloid cell subsets isolated
from peripheral blood and tumor biopsies of meningioma
patients. Given the presence of myeloid cells with the pheno-
type of MDSC in the peripheral blood of meningioma patients
and the expression at tumor level of markers of immunosup-
210 pression, we set out to test the potential suppressive activity of
myeloid populations present both in the blood and in tumor
biopsies. The whole CD14C cell population and two MDSC
subsets, one monocytic (MDSC 4) and one immature (MDSC 3
or e-MDSC), were separated either by magnetic beads (total
215CD14C cells) or by FACS sorting (MDSC 4 and 3) from the
PBMCs of HDs and meningioma patients, and their immuno-
suppressive ability was tested on the proliferation of mitogen
activated, CellTrace-labelled T cells. CD14C/HLA-DRlow/¡ and
Lin¡/HLA-DR¡ cells were chosen among patients in which a
220signiﬁcant expansion of these cell subsets was present. Repre-
sentative examples shown in Fig. 3A, and cumulative data in
Fig. 3B show that the addition of monocytes or of cell subsets
corresponding to MDSC 4 and MDSC 3 from meningioma
patients or from HD did not induce immune suppression. As
Figure 3. Functional analysis of myeloid cells isolated from peripheral blood and
tumor tissue. A) CD14C cells (left plots), CD14C/HLA-DRlow/¡ cells and Lin¡/HLA-
DR¡ cells (lower plots) were separated from PBMCs, and while CD33C or CD33C/
HLA-DRCcells were isolated from biopsies (right plots) by immunomagnetic or
FACS sorting. The immunosuppressive activity of these populations was tested on
the proliferation of CellTrace-labelled allogeneic PBMCs activated with anti-CD3/
CD28 for four days. Representative examples from three meningioma patients are
reported (MG# 1, MG# 2 and MG# 3). Red peaks refer to activated T cells alone,
while grey peaks represent the proliferation of T cells in the presence of sorted
subsets of myeloid cells. B) The histograms show the proliferation of T cells cul-
tured alone (ﬁrst left histograms) or in the presence of different populations of
myeloid cells added at 1:1 ratio (n D 6 for CD14C cells, 3 for CD14C/HLA-DRlow/¡
cells and Lin¡/HLA-DR¡ cells isolated from PBMCs of HDs; n D 12 for CD14C cells,
4 for CD14C/HLA-DRlow/¡ cells and 3 for Lin¡/HLA-DR¡ cells isolated from PBMCs
of meningioma patients). Inhibition of T cell proliferation of CD33C (n D 3) or
CD33C/HLA-DRCcells (nD 6) isolated from tumor biopsies of meningioma patients
is showed in the right part of the graph. The proliferation of T cells calculated con-
sidering the absolute number of T cells is reported in black, while the percentage
of proliferating T lymphocytes as assessed by CellTrace proﬁle is reported in grey.
Mean § SE is reported. Mann-Whitney U test was performed between the immu-
nosuppression exerted by CD14C cells isolated from peripheral blood and that of
either total CD33C or CD33C/HLA-DRC cells from biopsies. Asterisks denote signiﬁ-
cant P values: P <. 05; P <.01.
B=w in print; colour online
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225 control, we also added PMN isolated from peripheral blood of
meningioma patients by dextran sedimentation that, similarly,
did not show inhibitory effect on the proliferation of T cells
(data not shown).
To evaluate the potential suppressive ability of myeloid cells
230 present in tumor biopsies, we sorted total CD33C cells or
CD33C/HLA-DRC subset for the samples with a higher cell
number. Representative examples reported in the right panels
of Fig. 3A and cumulative data of total CD33C cells isolated
from 3 patients and CD33CHLA-DRC cells from 6 patients
235 (right histograms of Fig. 3B) show that myeloid cells isolated
from meningioma biopsies exert strong immunosuppression
on the proliferation of T cells. By dividing myeloid cells isolated
from grade I (n D 5) and grade II (n D 4) meningioma patients
we observed a trend towards increased immunosuppression in
240 grade II meningioma patients, although not statistically signiﬁ-
cant (data not shown).
Discussion
The presence of an immune inﬁltrate is a common ﬁnding in
many tumors, but only in recent years it has become evident
245 that the type and the composition of this inﬁltrate has a rele-
vance to tumor progression.10 Most of the studies addressed
this topic in malignant tumors, while less is known in benign
tumors. In this study we identiﬁed a recurrent pattern of a large
leukocyte inﬁltration in WHO grade I/II meningioma biopsies;
250 such inﬁltrate contains a large proportion of myeloid cells, in
which there is the prevalence of cells with markers and mor-
phology of macrophages endowed with suppressive activity.
Interestingly, we found a higher presence of suppressive macro-
phages in grade II meningiomas, compared to grade I tumors,
255 and this result supports the notion that tumor progression is
accompanied by an increased presence of an immune suppres-
sive microenvironment. Moreover, also the lymphoid compart-
ment shows signs of dysfunctional activity, since CD3CCD8¡ T
cells expressing LAG-3 are present at a higher level in grade II
260 meningiomas (Fig. 2F). To the best of our knowledge, these are
the ﬁrst indications that a benign tumor shows a progressive
dysfunctional and immune suppressive microenvironment
along its progression toward a malignant phenotype.
Another interesting observation of our results is the expan-
265 sion of myeloid cells bearing the markers of MDSCs, but lack-
ing immune suppressive activity on T cells, which is considered
the “gold” standard to deﬁne myeloid cells as MDSCs. Cur-
rently, such cells in the blood of meningioma patients should
be regarded as MDSC-like cells, as recently suggested by an
270 international committee.11 The ﬁnding that MDSC devoid of
suppressive activity are present in the blood of patients with a
benign tumor needs to be expanded to other benign tumors
and raises the intriguing possibility that the modulation of the
immune suppressive activity in these cells is a distinct event
275 from the mobilization of the cells from the bone marrow.
In line with these ﬁndings, we also found an increased level of
ARG-1 in the plasma of meningioma patients, which did not cor-
relate with an increased activity of the protein. Even though this
result seems in line with the lack of suppressive activity of circu-
280 lating myeloid cells, it should also be considered that published
results12 have clearly indicated that the formation of ornithine, at
high ARG-1 concentration, is limited by decreasing arginine
availability. Moreover, our activity test was performed at alkaline
pH at which only the full length ARG-1 is active but not
285the ARG-1 cleaved form, which has been described to be secreted
by PMN and has an optimal pH around 7.13 Therefore, further
studies are needed to clarify whether ARG-1 present in the
plasma of meningioma patients is functionally active.
At the tumor site, we sorted CD33C/HLA-DRC cells that are
290likely constituted by both resident and bone-marrow derived
macrophages and MDSC 1. These cells display morphological
features of macrophages and in this study we proved that they
have a relevant immunosuppressive activity. The presence of
tumor-associated macrophages in meningioma is in line with
295other studies.14–19 Myeloid cells have been characterized by
CD68 expression14,19 together with CD14, HLA-DR and
CD163 expression15,17 and described as a heterogeneous popu-
lation composed of round, oval, ameboid or ramiﬁed mononu-
clear cells with small, dense nuclei together with mononuclear
300cells with slight to marked vacuolation,16 all morphologic char-
acteristics that we found also in our cytospin evaluation. Differ-
ently from Domingues et al.,18 in our analyses we also observed
a myeloid cell population with low expression of HLA-DR that
morphologically corresponds to granulocytes. This discrepancy
305could be due to different methods of sample handling, since we
processed and analyzed biopsies immediately after withdraw-
ing, thus preventing PMN loss that are highly sensitive to cryo-
preservation.20 Of note, a number of studies pointed out that
tumor microenvironment has a profound effect on MDSCs,
310and that a complex interplay takes place among tumor reprog-
rammed myeloid cells present in the tumor microenviron-
ment.21 It should also be considered that differences between
tumor-associated macrophages (TAMs) and MDSCs cannot be
clearly deﬁned in the tumor microenvironment, as the bound-
315aries becomes rather blurry, given also the inherent plasticity of
TAMs and cellular heterogeneity of MDSCs. Moreover, we
showed that MDSCs change their phenotype and become
immunosuppressive only after having encountered activated T
cells because a crosstalk between the two populations activates
320a loop of molecular events that “prime” MDSC functions. We
also showed that molecules involved in this activation loop are
expressed in melanoma and colorectal cancer metastases, thus
highlighting that “MDSC priming” takes place at the tumor
site, where MDSCs and activated T cells are in contact.7
325Our data highlight the immunosuppressive function of
CD33C/HLA-DRC cells inﬁltrating meningioma biopsies, and
is emphasized by the statistically signiﬁcant difference in the
percentage of these cells between grade I and grade II meningi-
omas. Moreover, immunosuppressive CD33C/HLA-DRC cells
330also expressed PD-L1, a marker associated to impaired immune
responses in cancer patients22 and that we previously demon-
strated to be involved in MDSC mechanism of action.7 We
found PD-L1 expression at comparable levels in macrophages
and granulocytes present at the tumor site, and this expression
335was not associated to tumor grading, as grade I and II meningi-
omas had similar levels of PD-L1. Two other papers reported
similar results, documenting the expression of PD-L1 on
CD33C cells, but demonstrating also that it was not increased
in higher grade meningiomas. Both studies instead underlined
340that PD-L1 was expressed by tumor cells and that its levels
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increased with the progression of the disease.19,23 Moreover,
Han et al.19 identiﬁed PD-L1 expression on CD68¡ tumor cells
as an independent predictor of overall survival. We also found
high levels of PD-L1 expression in CD45¡ tumor cells, with
345 a trend to increase between grade I and II meningiomas,
although these levels did not reach a statistical signiﬁcance.
Besides myeloid cells, we found that leukocyte inﬁltrate in
meningioma biopsies contained also lymphocytes, constituted
for the vast majority by T cells with almost 50% of CD8C T
350 cells, in line with previous results18,19,23,24 and no differences
were observed with tumor grading (data not shown), as shown
by other studies.19,24 However, in grade III meningiomas Du
et al. reported a signiﬁcant decrease in the number of CD3C T
lymphocytes, both CD4C and CD8C, as compared to low-grade
355 meningiomas,23 thus suggesting that T cells are reduced in
high-grade meningiomas.
To further characterize the T cell inﬁltrate, we analyzed the
expression of two markers, PD-1 and LAG-3, which have been
associated to T cell impairment and involved in MDSC interac-
360 tion with T lymphocytes.7 We observed that PD-1 expression was
very high both on CD3CCD8¡ and on CD3CCD8C T cells. The
presence of PD-1 on T lymphocytes in meningioma biopsies was
already reported in two independent studies. One of them noted
a decrease in the number of PD-1C cells restricted to anaplastic
365 meningioma cases,23 the other showed a statistically signiﬁcant
increase of PD-1 expression in CD4C and CD8C tumor-inﬁltrat-
ing lymphocytes as compared to PBMCs.25 PD-1 up-regulation
was also associated to an increase of another marker of T cell
exhaustion, T cell immunoglobulin and mucin protein 3 (TIM-3),
370 although not statistical signiﬁcance was reached.25 In our study,
besides PD-1,we evaluated the expression of LAG-3, another
marker of T cell dysfunction, never investigated before in menin-
gioma patients and observed that LAG-3 was present on both
CD3CCD8¡ and CD3CCD8C T lymphocytes, although at lower
375 levels if compared to PD-1 expression, and moreover that its
expression is higher on CD3CCD8¡from grade II meningiomas,
thus highlighting a possible dysfunction in the T cell compart-
ment related to tumor progression.
In conclusion, in this study we observed in meningioma
380 patients the expansion of MDSC subsets, devoid of suppressive
activity. However, at the tumor site a large amount of suppres-
sive myeloid-inﬁltrating cells are present, suggesting that
MDSCs present in the peripheral blood may become function-
ally active only at tumor site, possibly undertaking a process of
385 differentiation into macrophages. All these data, together with
the presence of PD-1 and LAG-3 on T cells and the expression
of PD-L1 by both tumor and myeloid cells, suggest that an
immunosuppressive microenvironment is present in low-grade
meningioma patients, and support the possibility of using a
390 combined immunotherapeutic approach in grade II patients,
for which a clear therapeutic option is missing, in order to
relieve immune suppression and activate the immune activity
toward a growing tumor.
Materials and methods
395 Patients’ characteristics. Patients were recruited at the Depart-
ment of Neurosurgery, Padova University Hospital, Italy. The
ethical committee of the IOV-IRCCS and of Padova University
Hospital approved all experiments and all patients gave their
informed consent. We obtained peripheral blood and freshly
400resected tumor material from 34 patients: 24 affected by a
WHO grade I and 10 affected by a WHO grade II meningioma
(Table 1). One patient had four biopsies, three diagnosed as
grade I and one as grade II.
Blood and tumor samples. Blood sample was withdrawn
405from the patient the same day of surgery, before anesthesia
induction. Whole blood was used for ﬂow cytometry analysis,
while for functional assays peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifugation on
Ficoll-Paque PLUS (GE Healthcare-Amersham, NJ, USA), fol-
410lowed by dextran sedimentation to obtain PMNs, as previously
described.26 To produce single-cell suspension, all tumors were
processed by enzymatic digestion using Tumor Dissociation
Kit, human (MiltenyiBiotec), following manufacturer’s instruc-
tions for soft tumors. Red blood cells were lysed by hypotonic
415solution of ammonium chloride.
Multiparametric ﬂow cytometry. Peripheral blood and
tumor cell suspensions were analyzed by multicolor ﬂow
cytometry to determine levels of myeloid and T cell subsets.
Blood MDSC subsets were identiﬁed by a 7-color staining, con-
420taining anti-CD11b Alexa700 (BD Biosciences), anti-CD14
APC-H7 (BD Biosciences), anti-CD15 V450 (BD Biosciences),
anti-CD33, anti-a chain of interleukin 4 receptor (IL4Ra),
Lineage cocktail (Lin), anti-HLA-DR as reported in.5 Standard-
ization of the immunophenotyping assay was performed as
425described in.5
Biopsies were labelled with LIVE/DEAD Fixable Aqua (Life
Techonologies, MA, USA), anti-CD45 BV421 (BD Bioscien-
ces), anti-CD33 PE-Cy7 (eBioscience) or anti-CD33 APC (BD
Biosciences), anti-HLA-DR APC (BD Biosciences), anti-IL4Ra
430PE (R&D SYSTEMS), Lin cocktail 1 FITC (BD Biosciences),
anti-CD11b Alexa700 (BD Pharmingen), anti-PD-L1 PE (eBio-
science), anti-CD14 APC-H7 (BD Biosciences), anti-CD15
FITC (BD Biosciences), anti-CD3 PE-Cy7 (Beckman Coulter),
anti-CD8 APC-H7 (BD Biosciences), anti-LAG-3 FITC (Adip-
435oGen), anti-PD1 PE (MiltenyiBiotec). Data were acquired with
a LSRII ﬂow cytometer (BD Biosciences) and analysis was per-
formed by FlowJo software (Three Star Inc). Fluorescence
minus one (FMO) controls for HLA-DR, IL4Ra, PD-L1, PD-1
and LAG-3 were used as negative controls.
440Arginase type I ELISA. Plasma samples from meningioma
(n D 32) patients and healthy donors (n D 22) were obtained
upon previous centrifugation over Ficoll-Paque Plus of periph-
eral blood. The supernatant was collected and further spun at
1,300 rpm, 4 C for 6 minutes and stored at ¡80C. Plasma
445level of arginase type I (ARG1) was analyzed using Arginase
Liver Type Human ELISA (BioVendor Laboratory Medicine
Inc.) following the manufacturer’s instructions. Hemolized
samples were excluded from the analysis. Samples were assayed
in duplicates and ARG1 concentration was extrapolated from
450the standard curve.
Arginase activity assay. Plasma samples from meningioma
patients (n D 32) and healthy donors (n D 22), obtained as
before, were tested for arginase activity by measuring the pro-
duction of L-ornithine. Brieﬂy, 25ml of MnCl2 21.6 mMwere
455added to 30 ml of plasma and the mixture was heated at 55C
for 20 minutes to activate arginase. Then, 150ml of carbonate
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buffer (100 mM, pH 10) and 50ml L-arginine (100 mM) were
added and the reaction was further incubated at 37C for 10
minutes. The hydrolysis reaction converting L-arginine to L-
460 ornithine was identiﬁed by a colorimetric assay after the addi-
tion of ninhydrin solution and incubation at 100C for 30
minutes. Absorbance was acquired at 490 nm. Samples were
assayed in duplicates and L-ornithine concentration was
derived from a standard curve.
465 Isolation of myeloid cell subsets and proliferation assay.
CD14C cells were isolated from PBMCs of HDs and meningioma
patients by either immunomagnetic cell sorting using anti-CD14
beads (Miltenyi Biotec), following manufacturer’s instructions or
by FACS (MoﬂoAstrios, Beckman Coulter). CD14C/HLA-DRlow/¡
470 and Lin¡/HLA-DR¡ cells were separated by FACS sorting upon
PBMC staining after staining PBMCs with anti-CD14 FITC or
with the Lineage cocktail (anti-CD14, anti-CD19, anti-CD56,
anti-CD3) FITC and anti- HLA-DR APC. To separate CD33C
and CD33C/HLA-DRC cells present in the tumor, the cell suspen-
475 sion obtained after enzymatic digestion of meningioma biopsies
was stained with BD Horizon Fixable Viability Stain 520 (BD Bio-
sciences), anti-CD45 BV421 (BD Biosciences), anti-CD33 PE-Cy7
(eBioscience) and HLA-DR APC (BD Biosciences) and ﬁltered
through a 100 mM cell strainer. CD33C and CD33C/HLA-DRC
480 cell subsets were separated by FACS sorting. The purity of each
fraction was >90%. The immunosuppressive activity of
CD14Ccells isolated from the peripheral blood and of CD33C or
CD33C/HLA-DRC cells isolated from tumor was tested on the
proliferation of PBMCs isolated from the peripheral blood of
485 healthy donors by density gradient centrifugation on Ficoll-Paque
PLUS (GE Healthcare-Amersham, NJ, USA), as previously
described.26 PBMCs were stained with 0.5 mM CellTraceTM Violet
Cell Proliferation Kit (Invitrogen, Molecular Probes, MA, USA),
according to manufacturer’s instructions. CellTrace-labelled
490 PBMCs were activated with coated 1mg/ml anti-CD3 and 5 mg/
ml soluble anti-CD28 (BioLegend, CA, USA) for four days and
co-cultured in ﬂat bottom 96 or 384 well plates at the 1:1 ratio
with myeloid cells separated from peripheral blood or biopsies of
meningioma patients. Cell cultures were incubated at 37C and
495 5% CO2 in arginine free-RPMI (Biological Industries, Kibbutz
Beit Haemek, Israel), supplemented with 150 mM arginine, 10%
FBS. Proliferation of T cells was evaluated by assessing the signal
of CellTrace on CD3C cells and TruCountTM tubes (BD Bioscien-
ces) were used to determine the absolute number of CD3C cells
500 in the samples. Immunosuppression was calculated considering
the absolute number of proliferating T cells, or analyzing the per-
centage of proliferating cells from generation 3 onwards as
assessed by CellTrace proﬁle. In both cases data were normalized
assuming the proliferation of T cells cultured alone as 100%.
505 Cytological preparations and May-Gr€unwald-Giemsa
(MGG) staining. Cytospins were obtained by centrifuging 2.5
£ 104 cells on microscope slides by Shandon Cytospin 3 centri-
fuge. MGG staining was performed using the MGG kit for
smears (Bio-Optica), following manufacturer’s instructions.
510 Cell morphology was examined using a Olympus BX-40 micro-
scope (Leica Microsystems) with Leica lenses at 40 £ magniﬁ-
cation. Pictures were taken using a Leica DFC 295 camera
(Vashaw Scientiﬁc Inc) and acquired with Leica Application
Suite Version 4.1.0 (Meyer Instruments).
515Statistical analysis. Mann-Whitney U-test was used to com-
pare the groups of samples. Differences were considered statis-
tically signiﬁcant with P<0.05. All statistical analyses were
performed using the Sigmaplot software (Systat Software Inc.,
CA, USA). Absence of signiﬁcance was not reported for brevity.
520Abbreviations
ARG-1 Arginase-1
eMDSC early MDSC
FACS ﬂuorescence- activated cell sorting
525FMO ﬂuorescence minus one
FSC forward scatter
HD healthy donors
IL4Ra a chain of interleukin 4 receptor
LAG-3 lymphocyte-activation gene 3
530Lin lineage cocktail
MDSC myeloid-derived suppressor cell
MDSC-LC MDSC-like cells
MDSC 1 CD14C/IL4RaC cells
MDSC 2 CD15C/IL4RaCcells
535MDSC 3 Lin¡/HLA-DR¡/CD11bC/CD33C cells
MDSC 4 CD14C/HLA-DRlow/¡ cells
MG meningioma
MGG May-Gr€unwald Giemsa
M-MDSC monocytic MDSC
540n number
NA not applicable
PBMC peripheral blood mononuclear cell
PBL peripheral blood leukocytes
PD-1 programmed death 1
545PD-L1 Programmed death-ligand 1
PMN polimorphonuclear cell
PMN-MDSC polymorphonuclear MDSC
SD standard deviation
SE standard error
550SSC side scatter
TAM tumor-associated macrophage
TIM-3 T cell immunoglobulin and mucin protein 3
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